Surgical site infection by carbapenemase-producing Enterobacteriaceae. A challenge for today's surgeons

Cir Esp (Engl Ed). 2020 Jun-Jul;98(6):342-349. doi: 10.1016/j.ciresp.2019.11.006. Epub 2020 Jan 21.
[Article in English, Spanish]

Abstract

Introduction: Infections caused by carbapenemase-producing Enterobacteriaceae (CPE) are dramatically increasing worldwide, with an important impact on surgical patients. Our aim was to assess the clinical profile, outcomes, treatment, mortality and costs of CPE-related surgical site infection (SSI) in patients with abdominal surgery.

Methods: Review of CPE-related SSI in patients with abdominal surgery from January 2013 to December 2018. Patient factors and interventions present previously to the SSI identification were recorded, and a mortality analysis was also performed in patients with abdominal surgery and CPE-related organ/space SSI.

Results: Fifty patients were included: superficial incisional SSI 50%, deep incisional SSI 28%, organ/space SSI (or intra-abdominal infection) 70%. Klebsiella pneumoniae OXA-48 was present in 84%, and the most frequent were colorectal surgery (40%) and pancreatic surgery (20%). The antimicrobial susceptibility was: ceftazidime-avibactam 100%, amikacin 91.7%, tigecycline 89.1%, colistin 70.8%, meropenem 62.8%, imipenem 52.1%. An appropriate definitive antimicrobial treatment was administered in 86%, using a combined scheme in 76%. Global 30-day mortality rate for intra-abdominal infection was 20%, and mortality-related factors were: solid tumour (P=.009), solid metastasis (P=.009), septic shock (P=.02), blood transfusions (P=.03). Median global stay was 45 (IQR 26-67) days. Median global cost of hospitalization was €29,946 (IQR 15,405-47,749).

Conclusions: The clinical profile of patients with CPE-related SSI associates several comorbidities, interventions, prolonged stay and elevated costs. Mortality-related factors in intra-abdominal infection are solid tumour, metastasis, septic shock or blood transfusions.

Keywords: Antimicrobial stewardship; Carbapenem resistance; Carbapenemase-producing Enterobacteriaceae; Enterobacterias productoras de carbapenemasas; Infecciones quirúrgicas; Infección de sitio quirúrgico; Optimización de antibióticos; Pacientes quirúrgicos; Resistencia a carbapenémicos; Surgical infections; Surgical patients; Surgical site infection.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Carbapenem-Resistant Enterobacteriaceae / isolation & purification*
  • Chi-Square Distribution
  • Cross Infection / microbiology
  • Digestive System Surgical Procedures / adverse effects
  • Enterobacteriaceae Infections / drug therapy*
  • Enterobacteriaceae Infections / economics
  • Female
  • Health Care Costs
  • Hospitalization / economics
  • Humans
  • Intraabdominal Infections / microbiology
  • Klebsiella pneumoniae / isolation & purification
  • Male
  • Middle Aged
  • Statistics, Nonparametric
  • Surgical Wound Infection / drug therapy
  • Surgical Wound Infection / economics
  • Surgical Wound Infection / microbiology*
  • Surgical Wound Infection / mortality

Substances

  • Anti-Bacterial Agents